Myung In Pharm Co

Myung In Pharm Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Myung In Pharm Co (317450.KS) as of Nov 18, 2026 is 57.36 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 95.79 % — a change of -40.12% (lower).

FCF Conversion

57.36 %

YoY

-40.12%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Myung In Pharm Co is 2025 57.36 % . FCF Conversion Rate (FCF/EBITDA) of Myung In Pharm Co was 2024 95.79 % . It decreases by -40.12% lower compared to the previous year.

The Myung In Pharm Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
106.29 KRW
Jan 1, 2023
95.79 KRW
Jan 1, 2025
57.36 KRW
The Myung In Pharm Co FCF Conversion history
YEARFCF ConversionYoY
57.36 %-40.12%
95.79 %-9.87%
106.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myung In Pharm Co Stock analysis

What does Myung In Pharm Co do? Myung In Pharm Co., Ltd. generates revenue through the manufacture and sale of prescription drugs for neurology and psychiatry, including stroke and Parkinson’s disease treatments, schizophrenia, and depression therapies. The company primarily targets domestic and overseas markets, distributing its products under its own brand for neurological and psychiatric conditions. General pharmaceuticals such as dental, oral, digestive system treatments, and other related products form additional revenue streams within its domestic and international sales channels. The firm focuses on prescription drug segments, with key products addressing stroke, Parkinson’s disease, schizophrenia, and depression. These treatments are sold directly to healthcare providers and pharmacies in both domestic and overseas markets. The company also offers general pharmaceuticals like dental and oral treatments, alongside digestive system therapies, contributing to its diversified product portfolio across multiple therapeutic areas. Myung In Pharm’s business model relies on selling branded prescription medications for specific neurological and psychiatric conditions, alongside general pharmaceuticals. Its domestic and overseas market presence ensures consistent revenue from both regional and global healthcare sectors, with no additional details on specific customer segments or pricing strategies disclosed in the provided description. Myung In Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myung In Pharm Co stock

FCF Conversion Rate (FCF/EBITDA) of Myung In Pharm Co is 57.36 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Myung In Pharm Co changed from 95.79 % to 57.36 %, representing a -40.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Myung In Pharm Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Myung In Pharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Myung In Pharm Co

All Key Metrics — Myung In Pharm Co